Doses used in the research · reported as findings
PT-141 dosage, as the label and trials report it — not as a protocol.
The approved-label figure, the doses that appeared in research, the routes that were tried, and how long it actually lasts. Findings, attributed; never an instruction.
Before the details
A flat rule first: this page reports PT-141 dosage the way the label and the studies state it, and recommends nothing to anyone. The one approved figure is 1.75 mg injected under the skin, as needed, for low desire in premenopausal women — capped at one dose a day and eight a month [6]. Research used a few other doses for other purposes, which we list as history, not advice. It clears the blood fast (a few hours), even though its effect on the brain lasts much longer. The regulated product is a prefilled pen; 'research chemical' powder is a lab material only [6]. Everything below is a finding to read, never a protocol to follow — there is a real difference between knowing what a trial administered and being told what to do, and this page stays firmly on the first side of it.
The approved-label dose
For the approved HSDD indication in premenopausal women, the US prescribing information specifies bremelanotide 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month [6]. That is the entire labelled dosing instruction, reported here as a label finding.
The approved product is a single-use prefilled autoinjector — a pen, not a vial of powder to reconstitute [6]. That detail matters because it separates the regulated drug from the 'research chemical' form: the former is a finished, fixed-dose device, the latter is an unstandardised lab material with no oversight of identity, purity, or concentration [6].
Doses studied beyond the label
Other doses appear only in research, and only as findings. Phase 2 subcutaneous dose-finding in women studied 0.75, 1.25, and 1.75 mg before 1.75 mg was carried into the Phase 3 trials [6]. Early intranasal research in men with erectile dysfunction escalated to roughly 7-20 mg, with a statistically significant erectile response above 7 mg [1]. A Phase 1 metabolic study in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research protocol only [6].
None of these is a human-use instruction. They are the dose history of a molecule that was tested across several indications and routes before settling on one approved figure for one population. The spread is wide on purpose: a metabolic study probing appetite circuits needs a very different dosing pattern than an as-needed sexual-desire indication, and an intranasal erectile program in men is a different drug-delivery question again. Reading them together is useful only as history — it shows how much had to be narrowed down to reach the single 1.75 mg subcutaneous figure that survived [6].
Half-life and duration (~2.7 h)
Short in the blood, long in effect. After subcutaneous injection the terminal half-life is approximately 2.7 hours (range 1.9-4.0 h), with median Tmax around 0.5-1.0 hours [6]. Early intranasal studies reported a half-life of about 1.85-2.09 hours [6].
Here is the part that confuses people: the MC4R fMRI study observed increased sexual desire for up to 24 hours despite that short plasma half-life [5]. The molecule is long gone from the blood while the central effect persists — more evidence that it works by changing brain processing rather than by maintaining a circulating level [5][6].
How long does PT-141 last?
In the blood, not long — a terminal half-life around 2.7 hours after subcutaneous dosing [6]. Functionally, longer: the fMRI study measured increased desire for up to 24 hours, because the effect is a central change rather than a blood-level one [5][6].
Why it is an as-needed drug, not a daily one
The schedule is part of the design, not an afterthought. The approved figure is dosed as needed, at least 45 minutes before anticipated activity — not on a fixed daily clock — which sets it apart from the other approved HSDD medication, a daily oral drug [6]. The as-needed model leans on the same wiring-not-plumbing fact: because the central effect outlasts the molecule, a single pre-event dose is enough to act, and a standing daily level is not the mechanism [5][6].
The caps exist for a reason. No more than one dose per 24 hours and no more than 8 per month is the labelled ceiling, and it tracks the tolerability and pigmentation picture — more frequent dosing is exactly where nausea accumulates and where focal skin and gum darkening has been reported [4][6]. Read those caps as the label's own acknowledgement that the cost rises with frequency, not as an arbitrary limit.
Pharmacokinetics and the routes studied
The full PK, from the label: volume of distribution about 25.0 L, clearance about 6.5 L/hr, roughly 21% serum protein binding, metabolism by hydrolysis of the cyclic-peptide bonds and peptidase digestion, and excretion 64.8% renal and 22.8% fecal on a radiolabeled dose [6].
Three routes were studied: subcutaneous (the approved route), intranasal (early development, discontinued for pharmacokinetic variability), and intravenous (early pharmacology) [6]. The intranasal program is the instructive failure — it reported a slightly shorter half-life of about 1.85-2.09 hours but was abandoned because the dose that actually reached the bloodstream varied too much from one administration to the next, which is a fatal problem for a drug you are meant to time to within an hour [6]. The cyclic lactam ring is what makes the molecule more stable than linear melanocortin peptides, and it is the reason the subcutaneous as-needed schedule is practical at all [6]. None of this is reconstitution or self-administration guidance — the approved form arrives ready in a pen, and the research-chemical form is a laboratory material [6].